Matches in Nanopublications for { ?s ?p "[The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP620556.RAn1R4eEkpbQWgZE40BHG-lrpINnpyzr65R2gakymy7Og130_assertion description "[The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP620556.RAn1R4eEkpbQWgZE40BHG-lrpINnpyzr65R2gakymy7Og130_provenance.
- NP462937.RAUPX49U_3jB_l7OfnFjdJTtLj8i4uSXiF48NOx7wdAJg130_assertion description "[The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP462937.RAUPX49U_3jB_l7OfnFjdJTtLj8i4uSXiF48NOx7wdAJg130_provenance.
- assertion description "[The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP938202.RAT793XivxlSdkFYfxGZ9A528C44Ar_uMssIhGuxv1Qmo130_assertion description "[The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP938202.RAT793XivxlSdkFYfxGZ9A528C44Ar_uMssIhGuxv1Qmo130_provenance.
- NP938204.RAQ7_BWlmUA6TcAOxlHjYvWTdf5EAgJJgv7y74yve4D_Y130_assertion description "[The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP938204.RAQ7_BWlmUA6TcAOxlHjYvWTdf5EAgJJgv7y74yve4D_Y130_provenance.
- NP524655.RACDUy2FKnNDrFJjI8fu2nkRNC001fa-XT1hEh_edTOfk130_assertion description "[The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP524655.RACDUy2FKnNDrFJjI8fu2nkRNC001fa-XT1hEh_edTOfk130_provenance.
- NP452214.RAoXESbNqZesqW9qqAmToWeD6n_BrJD2eROb0KJ4ZrlLU130_assertion description "[The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP452214.RAoXESbNqZesqW9qqAmToWeD6n_BrJD2eROb0KJ4ZrlLU130_provenance.
- NP422713.RAGqE9RE-2hRIr9jYGXa9wB0yFWwBHURnoqCVd4GVpfX0130_assertion description "[The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP422713.RAGqE9RE-2hRIr9jYGXa9wB0yFWwBHURnoqCVd4GVpfX0130_provenance.
- NP938203.RAFIa2P0sbJ4iaT8oG4czqoR3vx1n2ScmUlmQc_hSKZuM130_assertion description "[The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP938203.RAFIa2P0sbJ4iaT8oG4czqoR3vx1n2ScmUlmQc_hSKZuM130_provenance.